Biotech/Pharmaceuticals
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Del.icio.us
- Digg
- StumbleUpon
Shares of Pfizer (PFE - Cramer's Take - Stockpickr) got a much-needed boost Wednesday as the world's No. 1 drugmaker said a new study showed its allergy drug Zyrtec outperformed Sanofi-Aventis' (SNY - Cramer's Take - Stockpickr) Allegra. Pfizer said that a study of almost 600 showed Zyrtec provided on average 14% greater symptom relief than Allegra for people who suffer from seasonal allergic rhinitis and documented ragweed sensitivity. The results applied to the entire period of five to 12 hours after patients took the drug. The Pfizer-sponsored study was presented at the 62nd annual meeting of the American College of Allergy, Asthma and Immunology. Zyrtec is a prescription antihistamine for the treatment of seasonal and perennial allergies, as well as chronic hives in adults and children, according to Pfizer. Pfizer shares have slumped lately in the wake of Merck's (MRK - Cramer's Take - Stockpickr) recall of its arthritis drug Vioxx because of health safety issues. The move has raised concerns about Pfizer's drugs Celebrex and Bextra, which come from the same family of drugs. Shares rose 64 cents, or 2.3%, to $27.96.
08/05/08
Three Internet Stocks That Could Double
These forgotten Internet stocks are being accumulated by hedge funds.
08/15/08
The Five Dumbest Things on Wall Street
Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...
08/15/08
McCain Fund-Raising Picks Up
The GOP presidential candidate raised $27 million in July.
08/15/08
Cash-Back Cards Aren't Money in the Bank
Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.
More popular tickers are indicated by scale.
Sponsored by:
RSS
